Pub Date : 2025-12-11DOI: 10.1016/j.jcpo.2025.100677
Chiara De Marchi , Federica Di Lullo , Caterina Ferrari , Valentina Pettinicchio , Alessandra Sinopoli , Paolo lombardo , Maria Elena Tosti , Silvia Declich , Scilla Pizzarelli , Franca D’Angelo , Maria Teresa Riccardi , Fabiana Arrivi , Francesca Maria Forestiero , Virginia Rosca , Alessandra Romano , Daniela Marotta
Introduction
Adherence to cancer screening programs is crucial for reducing cancer-related mortality, yet migrant and ethnic minorities (MEMs) often show lower participation rates compared to the general population. This systematic review aims to identify effective strategies to improve cancer screening adherence among MEMs in the WHO European Region.
Methods
A systematic review was conducted following PRISMA guidelines, searching Medline, Embase, Scisearch, and Biosis for studies published up to October 13th, 2025. Eligible studies included quantitative and quali-quantitative studies focused on interventions aimed to increase adherence to cancer screening among MEMs. Study quality was assessed using the Joanna Briggs Institute Critical Appraisal Tools.
Results
We included 12 studies, conducted in the United Kingdom, Norway, Israel, and Turkey. All of the interventions focused on breast and cervical cancer screening, with no studies addressing colorectal cancer screening. Effective interventions incorporated culturally and linguistically tailored strategies, such as community-based education, use of cultural mediators, multilingual reminds and information, free transport service and language support. Community-based and informal health education approaches significantly increased screening uptake, particularly among South Asian and ultraOrthodox Jewish women. However, interventions targeting men or colorectal cancer screening were lacking, indicating a significant research gap.
Policy Summary
This review highlights the need for gender-inclusive, culturally sensitive policies to improve screening adherence among MEMs. Policymakers should develop integrated screening campaigns that address multiple cancer types, particularly colorectal cancer, and ensure the inclusion of male populations. Enhancing community involvement is essential to achieve equitable screening coverage in line with EU health targets.
{"title":"Interventions to improve cancer screening adherence in migrants and ethnic minorities in the European Region: A systematic review.","authors":"Chiara De Marchi , Federica Di Lullo , Caterina Ferrari , Valentina Pettinicchio , Alessandra Sinopoli , Paolo lombardo , Maria Elena Tosti , Silvia Declich , Scilla Pizzarelli , Franca D’Angelo , Maria Teresa Riccardi , Fabiana Arrivi , Francesca Maria Forestiero , Virginia Rosca , Alessandra Romano , Daniela Marotta","doi":"10.1016/j.jcpo.2025.100677","DOIUrl":"10.1016/j.jcpo.2025.100677","url":null,"abstract":"<div><h3>Introduction</h3><div>Adherence to cancer screening programs is crucial for reducing cancer-related mortality, yet migrant and ethnic minorities (MEMs) often show lower participation rates compared to the general population. This systematic review aims to identify effective strategies to improve cancer screening adherence among MEMs in the WHO European Region.</div></div><div><h3>Methods</h3><div>A systematic review was conducted following PRISMA guidelines, searching Medline, Embase, Scisearch, and Biosis for studies published up to October 13th, 2025. Eligible studies included quantitative and quali-quantitative studies focused on interventions aimed to increase adherence to cancer screening among MEMs. Study quality was assessed using the Joanna Briggs Institute Critical Appraisal Tools.</div></div><div><h3>Results</h3><div>We included 12 studies, conducted in the United Kingdom, Norway, Israel, and Turkey. All of the interventions focused on breast and cervical cancer screening, with no studies addressing colorectal cancer screening. Effective interventions incorporated culturally and linguistically tailored strategies, such as community-based education, use of cultural mediators, multilingual reminds and information, free transport service and language support. Community-based and informal health education approaches significantly increased screening uptake, particularly among South Asian and ultraOrthodox Jewish women. However, interventions targeting men or colorectal cancer screening were lacking, indicating a significant research gap.</div></div><div><h3>Policy Summary</h3><div>This review highlights the need for gender-inclusive, culturally sensitive policies to improve screening adherence among MEMs. Policymakers should develop integrated screening campaigns that address multiple cancer types, particularly colorectal cancer, and ensure the inclusion of male populations. Enhancing community involvement is essential to achieve equitable screening coverage in line with EU health targets.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100677"},"PeriodicalIF":2.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-10DOI: 10.1016/j.jcpo.2025.100674
Mohammad Afshar Ali , Christine Y. Lu
Background
Prior studies estimated lung cancer costs; none examined quality of life and work productivity in Australia via population-based models.
Objective
Quantify lung cancer’s burden in working-age Australians using a dynamic Markov lifetable, estimating quality-adjusted life years (QALYs) and productivity-adjusted life years (PALYs) lost.
Methods
We developed a dynamic comparative Markov lifetable model to simulate both incident and prevalent cases of lung cancer among Australians aged 20–64 years from 2022 to 2031. Two parallel scenarios were modelled: (i) a base-case scenario reflecting individuals diagnosed in 2022 (incident model) and those living with lung cancer from 2012 to 2021 (prevalent model), and (ii) a counterfactual scenario in which no individuals had lung cancer. The differences between these simulations were used to estimate life years, QALYs, and PALYs lost. Model inputs were derived from previously published data. The economic value of productivity losses was estimated using the 2022 Australian gross domestic product (GDP) per full-time equivalent worker, applying a 5 % annual discount rate.
Results
Over the twenty-year period, lung cancer is projected to result in the loss of 28,430 life years, 55,964 QALYs, and 60,310 PALYs, equating to AU$14.45 billion in lost GDP. Sensitivity analyses confirmed the robustness of the model to variations in key parameters.
Conclusion
Lung cancer imposes a substantial health and economic burden among working-age Australians. By combining QALY and PALY metrics within a dynamic modelling framework, this study provides a comprehensive assessment of the burden faced by this population and may inform future research and economic evaluations.
{"title":"The health and economic burden of lung cancer in Australia: A dynamic model of quality of life and productivity loss","authors":"Mohammad Afshar Ali , Christine Y. Lu","doi":"10.1016/j.jcpo.2025.100674","DOIUrl":"10.1016/j.jcpo.2025.100674","url":null,"abstract":"<div><h3>Background</h3><div>Prior studies estimated lung cancer costs; none examined quality of life and work productivity in Australia via population-based models.</div></div><div><h3>Objective</h3><div>Quantify lung cancer’s burden in working-age Australians using a dynamic Markov lifetable, estimating quality-adjusted life years (QALYs) and productivity-adjusted life years (PALYs) lost.</div></div><div><h3>Methods</h3><div>We developed a dynamic comparative Markov lifetable model to simulate both incident and prevalent cases of lung cancer among Australians aged 20–64 years from 2022 to 2031. Two parallel scenarios were modelled: (i) a base-case scenario reflecting individuals diagnosed in 2022 (incident model) and those living with lung cancer from 2012 to 2021 (prevalent model), and (ii) a counterfactual scenario in which no individuals had lung cancer. The differences between these simulations were used to estimate life years, QALYs, and PALYs lost. Model inputs were derived from previously published data. The economic value of productivity losses was estimated using the 2022 Australian gross domestic product (GDP) per full-time equivalent worker, applying a 5 % annual discount rate.</div></div><div><h3>Results</h3><div>Over the twenty-year period, lung cancer is projected to result in the loss of 28,430 life years, 55,964 QALYs, and 60,310 PALYs, equating to AU$14.45 billion in lost GDP. Sensitivity analyses confirmed the robustness of the model to variations in key parameters.</div></div><div><h3>Conclusion</h3><div>Lung cancer imposes a substantial health and economic burden among working-age Australians. By combining QALY and PALY metrics within a dynamic modelling framework, this study provides a comprehensive assessment of the burden faced by this population and may inform future research and economic evaluations.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100674"},"PeriodicalIF":2.0,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145744733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-09DOI: 10.1016/j.jcpo.2025.100678
Rashidul Alam Mahumud
Australia has strong cancer survival. Yet many people still struggle to get timely diagnosis, medicines, and supportive care. Gaps are widest for Aboriginal and Torres Strait Islander peoples, rural and remote communities, culturally and linguistically diverse groups, people with disability, temporary visa holders, and people experiencing homelessness.
Objective
To set out practical, rights-aligned actions that turn universal coverage into universal access.
Approach
This short communication applies a rights-based analytic framing, distinct from a checklist, to reinterpret policy choices through the lenses of accountability, justiciability, and participation.
Actionable implications
Using this framing, synthesising recent evidence on affordability, diagnostics, and service capacity, we prioritise four actionable levers: cap financial toxicity (with standardised travel/accommodation support and public OOP reporting); fund and benchmark companion diagnostics (national turnaround and equity dashboards); scale tele-oncology/tele-trials with minimum local capacity and travel stipends (monitoring priority populations); and adopt distributional cost-effectiveness analysis in HTA and program design to make equity trade-offs explicit. This framing specifies who must act, by when, and with what evidence, offering a practical route to equitable, sustainable cancer.
Conclusion
Universal coverage alone does not guarantee equity. Implementing a rights-aligned plan with clear duty-bearers, timelines, and the four actionable levers we outline can narrow access gaps and support timely, affordable, culturally safe cancer care, including for people experiencing homelessness.
{"title":"Ensuring equitable access to cancer medicine and care in Australia: A human-rights lens, including people experiencing homelessness","authors":"Rashidul Alam Mahumud","doi":"10.1016/j.jcpo.2025.100678","DOIUrl":"10.1016/j.jcpo.2025.100678","url":null,"abstract":"<div><div>Australia has strong cancer survival. Yet many people still struggle to get timely diagnosis, medicines, and supportive care. Gaps are widest for Aboriginal and Torres Strait Islander peoples, rural and remote communities, culturally and linguistically diverse groups, people with disability, temporary visa holders, and people experiencing homelessness.</div></div><div><h3>Objective</h3><div>To set out practical, rights-aligned actions that turn universal coverage into universal access.</div></div><div><h3>Approach</h3><div>This short communication applies a rights-based analytic framing, distinct from a checklist, to reinterpret policy choices through the lenses of accountability, justiciability, and participation.</div></div><div><h3>Actionable implications</h3><div>Using this framing, synthesising recent evidence on affordability, diagnostics, and service capacity, we prioritise four actionable levers: cap financial toxicity (with standardised travel/accommodation support and public OOP reporting); fund and benchmark companion diagnostics (national turnaround and equity dashboards); scale tele-oncology/tele-trials with minimum local capacity and travel stipends (monitoring priority populations); and adopt distributional cost-effectiveness analysis in HTA and program design to make equity trade-offs explicit. This framing specifies who must act, by when, and with what evidence, offering a practical route to equitable, sustainable cancer.</div></div><div><h3>Conclusion</h3><div>Universal coverage alone does not guarantee equity. Implementing a rights-aligned plan with clear duty-bearers, timelines, and the four actionable levers we outline can narrow access gaps and support timely, affordable, culturally safe cancer care, including for people experiencing homelessness.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100678"},"PeriodicalIF":2.0,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-06DOI: 10.1016/j.jcpo.2025.100675
Tianjiao Gao , Marwa Farag , Sohail Agha , Linda Mobula , Xiaohui Hou , Guohong Li , Wu Zeng
Background
This study retrospectively examines the cost-effectiveness of the national HPV vaccination program using the program cost and coverage data in Nigeria.
Methods
We conducted a cost-effectiveness analysis of the HPV vaccination program compared with no vaccination in Nigeria, adopting both health system and societal perspectives. A static Markov model simulating HPV infection and cervical cancer outcomes was developed for a cohort of girls aged 9–14 years, followed until age 100. The model comprised primarily the following health states: susceptible, cervical cancer, and death. It further incorporated three additional pathways for patients with cervical cancer, including those with successful treatment, with treatment failure, and with no treatment.
Results
The incremental cost-effectiveness ratio (ICER) was estimated at $268.67 per quality-adjusted life year (QALY) gained from the health system perspective and $217.85 per QALY gained from the societal perspective. Both ICERs were well below the cost-effectiveness threshold of one-time GDP per capita in Nigeria ($806.95). Key drivers of cost-effectiveness included vaccine cost, treatment success rate, cervical cancer treatment coverage, and cervical cancer utility values.
Discussion
The single-dose HPV vaccination program is highly cost-effective in Nigeria, compared to the status quo of no vaccination. To ensure long-term sustainability, the Nigerian government should strengthen financing mechanisms and the healthcare system to support the program.
Policy Summary
Single dose HPV vaccination is cost-effective in Nigeria. It is crucial to obtain sustainable vaccine financing and improve treatment to maintain the program impact.
{"title":"Economic evaluation of the one-dose HPV vaccination program in Nigeria","authors":"Tianjiao Gao , Marwa Farag , Sohail Agha , Linda Mobula , Xiaohui Hou , Guohong Li , Wu Zeng","doi":"10.1016/j.jcpo.2025.100675","DOIUrl":"10.1016/j.jcpo.2025.100675","url":null,"abstract":"<div><h3>Background</h3><div>This study retrospectively examines the cost-effectiveness of the national HPV vaccination program using the program cost and coverage data in Nigeria.</div></div><div><h3>Methods</h3><div>We conducted a cost-effectiveness analysis of the HPV vaccination program compared with no vaccination in Nigeria, adopting both health system and societal perspectives. A static Markov model simulating HPV infection and cervical cancer outcomes was developed for a cohort of girls aged 9–14 years, followed until age 100. The model comprised primarily the following health states: susceptible, cervical cancer, and death. It further incorporated three additional pathways for patients with cervical cancer, including those with successful treatment, with treatment failure, and with no treatment.</div></div><div><h3>Results</h3><div>The incremental cost-effectiveness ratio (ICER) was estimated at $268.67 per quality-adjusted life year (QALY) gained from the health system perspective and $217.85 per QALY gained from the societal perspective. Both ICERs were well below the cost-effectiveness threshold of one-time GDP per capita in Nigeria ($806.95). Key drivers of cost-effectiveness included vaccine cost, treatment success rate, cervical cancer treatment coverage, and cervical cancer utility values.</div></div><div><h3>Discussion</h3><div>The single-dose HPV vaccination program is highly cost-effective in Nigeria, compared to the status quo of no vaccination. To ensure long-term sustainability, the Nigerian government should strengthen financing mechanisms and the healthcare system to support the program.</div></div><div><h3>Policy Summary</h3><div>Single dose HPV vaccination is cost-effective in Nigeria. It is crucial to obtain sustainable vaccine financing and improve treatment to maintain the program impact.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100675"},"PeriodicalIF":2.0,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145709939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bhutan has achieved 90–70–90 global targets by 2023, way ahead of the global targets of elimination of cervical cancer by 2030. However, cervical cancer remains the most prevalent cancer, among women in Bhutan. While all healthcare screening, diagnosis and treatment of cervical cancers are provided free of cost, sustainability in terms of financing and human resources and ensuring quality of services are the major challenges. Development of a national standard guideline is a major intervention towards improving the quality of colposcopy services and treatment of precancer in the country. In this article, we discuss the summary of the consensus-based practical guideline on colposcopy and treatment of cervical pre-cancers in Bhutan, challenges faced and potential way forward.
{"title":"Quality improvement initiatives on colposcopy and treatment of cervical pre-cancer services in Bhutan: Experiences, challenges, and way forward","authors":"Namkha Dorji, Thinley Dorji, Yeshey Dorjey, Yangdon Yangdon","doi":"10.1016/j.jcpo.2025.100676","DOIUrl":"10.1016/j.jcpo.2025.100676","url":null,"abstract":"<div><div>Bhutan has achieved 90–70–90 global targets by 2023, way ahead of the global targets of elimination of cervical cancer by 2030. However, cervical cancer remains the most prevalent cancer, among women in Bhutan. While all healthcare screening, diagnosis and treatment of cervical cancers are provided free of cost, sustainability in terms of financing and human resources and ensuring quality of services are the major challenges. Development of a national standard guideline is a major intervention towards improving the quality of colposcopy services and treatment of precancer in the country. In this article, we discuss the summary of the consensus-based practical guideline on colposcopy and treatment of cervical pre-cancers in Bhutan, challenges faced and potential way forward.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100676"},"PeriodicalIF":2.0,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145685016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1016/j.jcpo.2025.100673
Red Thaddeus D. Miguel, Isabella Steffensen
{"title":"Evidence on vaping e-cigarettes as a risk factor for cancer: A cautionary tale in flawed synthesis","authors":"Red Thaddeus D. Miguel, Isabella Steffensen","doi":"10.1016/j.jcpo.2025.100673","DOIUrl":"10.1016/j.jcpo.2025.100673","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"47 ","pages":"Article 100673"},"PeriodicalIF":2.0,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.jcpo.2025.100670
Linsey Eldridge, Amina Chtourou, Kalina Duncan, Leslie Given, Sana Haider, Karin Hohman, Douglas M Puricelli Perin, Yannick Romero, Zuzanna Tittenbrun, Mishka Kohli Cira
Background: As cancer incidence in low- and middle-income countries (LMICs) continues to rise, the development of National Cancer Control Plans (NCCP) has become an essential policy tool for guiding a comprehensive and coordinated response. The NCCP Development Research Initiative (NCCP DRIVE) is a qualitative study led by the International Cancer Control Partnership (ICCP) to understand the NCCP development process and contextual factors that may enable or impede effective NCCP development.
Methods: In-depth interviews were conducted with country-level cancer planners in nine countries (seven African, two South Asian) within the ICCP network. Transcripts were recorded, transcribed, and double-coded in Dedoose, then analyzed thematically using the Health Policy Triangle (HPT) framework.
Results: Findings highlight that NCCP development is dynamic and iterative, following six commonly reported phases: Initiation, Formulation, Negotiation, Communication, Implementation, and Monitoring/Evaluation. Common challenges reported by respondents included limited financial and human resources, competing priorities, fragmented health systems, and inadequate data. These constraints led to compressed timelines, overlapping planning activities, and gaps in costing and implementation plans. To address these challenges, respondents employed various strategies, including integrating cancer control efforts with existing health programs, engaging multisector actors, building political will, and securing technical assistance (TA) from partners. Building partnerships was pivotal, helping to set priorities, align plans with national and global agendas, and leverage resources. However, some respondents reported misaligned timelines and priorities, and coordination challenges.
Conclusion: This study contributes a policy framework-informed, implementation-focused analysis of NCCP development, offering practical insights into how countries navigate complex challenges to initiate and sustain cancer control planning. Findings underscore the need for flexible TA models and stronger data systems, and the value of integrating cancer control priorities within existing health systems. Understanding these dynamics from initiation to implementation offers practical insights for countries at various stages of development, and for partners providing technical assistance.
{"title":"Understanding the development process of national cancer control plans in low- and middle-income countries.","authors":"Linsey Eldridge, Amina Chtourou, Kalina Duncan, Leslie Given, Sana Haider, Karin Hohman, Douglas M Puricelli Perin, Yannick Romero, Zuzanna Tittenbrun, Mishka Kohli Cira","doi":"10.1016/j.jcpo.2025.100670","DOIUrl":"https://doi.org/10.1016/j.jcpo.2025.100670","url":null,"abstract":"<p><strong>Background: </strong>As cancer incidence in low- and middle-income countries (LMICs) continues to rise, the development of National Cancer Control Plans (NCCP) has become an essential policy tool for guiding a comprehensive and coordinated response. The NCCP Development Research Initiative (NCCP DRIVE) is a qualitative study led by the International Cancer Control Partnership (ICCP) to understand the NCCP development process and contextual factors that may enable or impede effective NCCP development.</p><p><strong>Methods: </strong>In-depth interviews were conducted with country-level cancer planners in nine countries (seven African, two South Asian) within the ICCP network. Transcripts were recorded, transcribed, and double-coded in Dedoose, then analyzed thematically using the Health Policy Triangle (HPT) framework.</p><p><strong>Results: </strong>Findings highlight that NCCP development is dynamic and iterative, following six commonly reported phases: Initiation, Formulation, Negotiation, Communication, Implementation, and Monitoring/Evaluation. Common challenges reported by respondents included limited financial and human resources, competing priorities, fragmented health systems, and inadequate data. These constraints led to compressed timelines, overlapping planning activities, and gaps in costing and implementation plans. To address these challenges, respondents employed various strategies, including integrating cancer control efforts with existing health programs, engaging multisector actors, building political will, and securing technical assistance (TA) from partners. Building partnerships was pivotal, helping to set priorities, align plans with national and global agendas, and leverage resources. However, some respondents reported misaligned timelines and priorities, and coordination challenges.</p><p><strong>Conclusion: </strong>This study contributes a policy framework-informed, implementation-focused analysis of NCCP development, offering practical insights into how countries navigate complex challenges to initiate and sustain cancer control planning. Findings underscore the need for flexible TA models and stronger data systems, and the value of integrating cancer control priorities within existing health systems. Understanding these dynamics from initiation to implementation offers practical insights for countries at various stages of development, and for partners providing technical assistance.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100670"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145670139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.jcpo.2025.100639
Linsey Eldridge, Kalina Duncan, Mishka Kohli Cira
{"title":"Response to ‘beyond virtual learning: Leveraging project ECHO to sustain and localize national cancer control plan implementation in LMICs’","authors":"Linsey Eldridge, Kalina Duncan, Mishka Kohli Cira","doi":"10.1016/j.jcpo.2025.100639","DOIUrl":"10.1016/j.jcpo.2025.100639","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100639"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.jcpo.2025.100667
Yasmin Jahan , Atiqur SM-Rahman
{"title":"Corrigendum to “Bridging the equity gap in colorectal cancer screening: A comparative analysis across high-income countries” [J. Cancer Policy 46 (2025) 100657]","authors":"Yasmin Jahan , Atiqur SM-Rahman","doi":"10.1016/j.jcpo.2025.100667","DOIUrl":"10.1016/j.jcpo.2025.100667","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100667"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号